item management s discussion and analysis of financial condition and results of operations 
introduction the company develops and markets proprietary pharmaceutical products in niche medical markets  consisting of approximately  or fewer physicians 
during  sales and cash flow from marinol and maxaquin  as well as cash from cash reserves  were used to fund product development programs and expand the company s sales and marketing infrastructure 
the company is actively pursuing acquisition of commercial products and rights to additional pharmaceutical products under late stage development or already on the market 
in  unimed s net sales were million  a increase over net sales of million 
marinol net sales increased by over due to growth in domestic sales and a price increase in the second quarter of maxaquin was introduced in the second quarter of contributing  to net sales 
the company reported a net loss of 
per share basic in compared to net income of 
per share basic in and 
per share basic in the net loss in was caused primarily by the write down of certain assets and investments totaling  or 
per share  a increase in sales and marketing expenses  and a increase in research and development spending 
in  the company used cash to support operations of  compared to generating cash flow from operations of  in the company reported year end cash  cash equivalents and short term investments of  compared with  at year end revenue fiscal net sales of marinol  marketed as a refractory antiemetic in cancer chemotherapy and an appetite stimulant in anorexia associated with weight loss in aids  increased over levels  ending the year at  this compares with a increase in marinol net sales growth for to  both the and marinol net sales increase were a result of increased unit sales and a price increase 
the company s licensee  roxane laboratories  inc roxane  markets marinol 
the company reports the royalty income it receives from roxane as revenues from marinol sales 
in  marinol was approved for use as an antiemetic in south africa and is currently under regulatory review for use as an appetite stimulant 
the antiemetic approval resulted in launching the product in south africa in july marinol sales to countries outside the united states totaled approximately  in and  in the company began to market maxaquin  a fluoroquinolone antibiotic  in the second quarter of net sales for the year totaled  other pharmaceutical companies in canada and several other international markets promote serc for the treatment of recurrent vertigo 
during  sanofi winthrop in canada marketed serc for the company 
in december  unimed entered into an agreement with solvay duphar whereby unimed licensed the rights to proprietary know how and manufacturing for the drug serc in the us as part of the agreement  the company received a million payment for product development and for unimed s product and trademark rights to serc in canada  australia and south africa 
royalties from serc sales in canada amounted to zero in and and  in total revenue for was  representing growth over  in higher marinol net sales  combined with maxaquin net sales were responsible for the increase 
for the year ended december   and for all prior periods presented  the company reclassified  for financial reporting purposes  all research and development revenues that were historically treated as part of total revenue 
these revenues are now offset against research and development expenses in the operating expenses section of the income statement 
this change had no effect on net income 
in  the company deferred the recognition of revenue on unconditional cash payments made from corporate partners that were to be applied to development of the company s product portfolio 
the company recognized the remaining portion of this deferred revenue in other income net of other expenses decreased approximately  or to  in primarily as a result of imputed interest expense of approximately  the maxaquin distribution agreement includes a long and short term debt obligation for which interest is imputed and recorded 
interest income decreased to  a  decrease from due to lower invested cash balances 
other income in includes  of clinical development milestone payments from a product sub license agreement 
in  other income included approximately  from the gain on a product sub license and  from a gain on the sale of a trademark 
other income in included a  write off of the company s interest in a limited partnership 
costs and expenses cost of sales improved by from  in to  in the lower cost of sales in was due to lower marinol raw material costs and maxaquin product costs which are lower than those of marinol 
cost of sales in was lower than the cost of sales of  due primarily to lower marinol raw material costs 
net research and development expenses increased from  in to  in as mentioned earlier  the company started three phase iii clinical trials during as well as several smaller studies such as the marinol alternate dosage form studies 
the company also prepared an nda for nitazoxanide and submitted it to the fda in december 
net research and development expenses increased from  in to  in with the completion of three human clinical studies and initiation of several toxicology studies 
for the year ended december   and for all prior periods presented  the company reclassified  for financial reporting purposes  all research and development revenues that were historically treated as part of total revenue 
these revenues are now offset against research and development expenses in the operating expenses section of the income statement 
this change had no effect on net income 
approximately  of deferred research and development expenditures were offset against research and development expenses in these deferred expenses would have historically been recognized as research and development revenue 
sales and marketing expenses increased from  in to  in during  the company organized an integrated sales and marketing infrastructure that can provide for the coordinated introduction of new products to targeted markets 
the increase can be attributed to increased personnel and advertising expenses related to the promotion of maxaquin 
sales and marketing expenses increased from to as the company added a commercial development function to distribute new products 
operating and administrative expenses increased from  in to  in primarily due to increased administrative support of the expanded sales and marketing activities and accelerated development programs  professional expenses related to the acquisition of product rights  higher personnel related expenses and executive recruitment 
operating and administrative expenses increased from to operating and administrative expenses as a percent of net sales were in and in both and operating and administrative expenses were  in liquidity and capital resources at december   the company had cash and cash equivalents and short term investments of  compared with  at december  during  unimed used cash in operations of  working capital decreased from  in to  in  primarily due to the purchase of maxaquin and anadrol product rights  the purchase of equipment and leasehold improvements and the purchase of company common stock 
the company expects to continue to increase clinical development expenditures in as it accelerates phase iii clinical trials 
the company will also continue to expand its sales and marketing efforts as it adds to the portfolio of products currently promoted 
in addition  the company will require a higher investment in working capital in order to fund accounts receivable and inventories 
during  the company received approximately  from the exercise of stock options 
the company purchased  of its own common stock  maintaining  shares in treasury as of december  inventories increased approximately  in over levels 
due to increasing marinol sales and production levels of thc remaining constant  thc inventory decreased during the year 
this was offset by inventory purchases related to maxaquin and anadrol 
also  the company increased the reserve for inventory obsolescence during the company s marinol distributor  roxane  advances funds to unimed to maintain marinol inventories 
the current liability  due to roxane  is relieved on a quarterly basis through the reduction of royalties payable to the company 
the reduction in the quarter s royalty payment primarily corresponds to the cost of marinol inventory sold during the quarter 
the company maintains cash reserves and short term investments to meet anticipated working capital  capital expenditures  research and development and other investment opportunities 
the company intends to acquire other product licenses  which may reduce cash balances 
accounting pronouncements the fasb has recently issued two new accounting standards  statement no 
 reporting comprehensive income and  statement no 
 disclosures about segments of an enterprise and related information  and if adopted will be effective for fiscal year the company is evaluating the effect  if any  of these new statements 
year program the company will continue to conduct a comprehensive review of its computer systems to identify the systems that could be affected by the year issue and is developing an implementation plan to resolve the issue 
the company presently believes that  with modifications to existing software and converting to new software  the year problem will not pose significant operational problems for the company s computer systems as so modified and converted 
however  if such modifications and conversions are not completed in a timely manner  the year problem may have a material impact on the operations of the company 
backlog  seasonality and impact of inflation sales orders are typically filled shortly after receipt 
in general  the company s products experience minor seasonal fluctuations 
while raw materials included in certain products are subject to price escalation  due to a limited number of suppliers  the complexity of manufacturing processes and regulatory procedures  the company does not attribute this to inflation and does not anticipate inflation to have a significant impact on costs in the near future 

